Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Juno Therapeutics, Inc.. (2/29/16). "Press Release: Juno Therapeutics Reports Fourth Quarter and 2015 Financial Results". Seattle, WA.

Organisations Organisation Juno Therapeutics Inc. (Nasdaq: JUNO)
  Group Juno Therapeutics (Group)
  Organisation 2 Stage Cell Therapeutics GmbH
  Today Juno Therapeutics GmbH
  Group Juno Therapeutics (Group)
Product Product  lisocabtagene maraleucel (liso-cel; JCAR017)
  Index term 2 Stage Cell Therapeutics–Juno Therapeutics: investment, 201505 acquisition remaining 95% for €52.5m cash upfront + 486.3k shares + €135m milestones
Person Person Bishop, Hans E. (Juno Therapeutics 201601 CEO + Co-Founder before Dendreon + Bayer + GW + SKB)
     


   
Record changed: 2017-10-01

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Juno Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top